- Viral Conjunctivitis
- Bacterial Conjunctivitis
- Allergic Conjunctivitis
- Conjunctivitis Caused by Irritants
Acute Conjunctivitis Treatment Market report gives a comprehensive outlook on global market scenario, growth trends, shares, with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The report on the global Acute Conjunctivitis Treatment market gives historical, current, and future market sizes (US$ Mn) on the basis of type, dosage form, drug class, distribution channel and region. This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyze the market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the report include manufacturers, distributors, policy makers, and service providers engaged in Acute Conjunctivitis Treatment.
Conjunctivitis, or pink eye, is an irritation or inflammation of the conjunctiva that covers the white part of the eyeball. It can be caused by allergies or a bacterial or viral infection. Conjunctivitis can be highly communicable and can be spread easily by contact with secretions of eye from the infected person. Symptoms includes tearing, itching and redness of the eyes. It can also lead to discharge or crusting around the eyes. It's important to stop wearing contact lenses whilst affected by conjunctivitis. Conjunctivitis often resolves on its own, but treatment can speed up the recovery process. Allergic conjunctivitis can be treated with antihistamines. Bacterial conjunctivitis can be treated with antibiotic eye drops.In June 2017, Teva Pharmaceuticals launched, generic version of Pataday (olopatadine hydrochloride ophthalmic solution) 0.2%, in U.S used to treat Allergic conjunctivitis In February 2015, Novartis division, Alcon has received USFDA approval for Pazeo(TM) (olopatadine hydrochloride ophthalmic solution) 0.7%, to treat ocular itching which is associated with allergic conjunctivitis.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Acute conjunctivitis treatment market is because of increasing aging of the population, increase in ophthalmic diseases prevalence rate, rise in investments for the development of new products, growing conscious towards health, funded eye check-up campaigns by governments of different countries are driving the growth of acute conjunctivitis treatment market. Moreover, increasing awareness about various eye infections and rise in blindness prevalence among geriatric population boosting the market growth of acute conjunctivitis treatment. However, due to the stringent regulations in drugs developmental process and side effects associated with the various antibiotics would hamper the adoption of eye infection pharmaceutical treatment, in turn, hinder the market growth.
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
[urltag url='request-table-of-content']